XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms XV CHINA SAS
- Sponsors Abbott Laboratories
- 03 Apr 2013 Planned End Date changed from 1 Mar 2017 to 1 Jan 2017 as reported by ClinicalTrials.gov.
- 07 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 13 Aug 2011 Planned number of patients changed to 2500.